Invitrocue was first founded in 2012 to commercialize proprietary 3D cell culture technology developed at A*STAR’s Institute of Bioengineering and Nanotechnology in Singapore, Massachusetts Institute of Technology Cambridge, and the Genome Institute of Singapore. These technologies and know how have since been successfully developed into commercial services such as in vitro Human Liver models for drug toxicology testing, in vitro Human NASH (Fatty Liver) model, in vitro Human Liver infection models, in vitro Human Respiratory models, in vitro Human Oncology Organoids and in vivo Humanized Immune Organoid.

These technologies are a key advancement in supporting the treatment in a range of cancers with leading global Cancer centers and leading pharmaceutical companies in their drug development programs. Invitrocue is headquartered in Singapore, with operations in Germany, Spain, Brazil, Australia, China, and Hong Kong.